Robb Knie CEO Hoth

Hoth Therapeutics a New York biotechnology company has recently names Robb Knie as Chief Executive Officer.  Hoth announced it has raised 3 million dollars in a series A funding.

Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth's BioLexa Platform.  Laidlaw & Co (UK) Ltd. ("Laidlaw") in New York served as the sole placement agent.